METHODS FOR INHIBITING ANGIOGENESIS IN A SUBJECT IN NEED THEREOF
In one aspect, the present invention provides methods for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from, or at risk for developing, an angiogenesis-dependent disease or condition, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis. In some embodiments of these aspects of the invention, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.
1 . A method for preventing, treating, reverting and/or delaying angiogenesis in a mammalian subject suffering from an angiogenesis-dependent cancer comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit angiogenesis, wherein the MASP-2 inhibitory agent is a MASP-2 inhibitory antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6.
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . The method of claim 1 , wherein the subject is suffering from an angiogenesis-dependent cancer selected from the group consisting of: solid tumor(s), blood borne tumors, high-risk carcinoid tumors, and tumor metastases.
8 . The method of claim 7 , wherein the subject is suffering from one or more solid tumors and the method comprises administering an amount of MASP-2 inhibitor effective to inhibit tumor angiogenesis.
9 . The method of claim 8 , wherein the subject is suffering from or at risk for tumor metastases and the method comprises administering an amount of MASP-2 inhibitor effective to inhibit tumor metastases.
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . The method of claim 1 , wherein the antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody and a human antibody.
14 . The method of claim 1 , wherein the composition is administered subcutaneously, intraperitoneally, intra-muscularly, intra-arterially, intravenously, or as an inhalant.
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . (canceled)
19 . A method of inhibiting tumor angiogenesis comprising inhibit angiogenesis.
20 . The method of claim 19 , wherein the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof.
21 . The method of claim 20 , wherein the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6.
22 . The method of claim 20 , wherein the antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody and a human antibody.